Last reviewed · How we verify
NCT05212571: KetCRPS-2
Long-term Pain Modulation by Intravenous Esketamine in CRPS
NA trial testing S-ketamine infusion inpatient setting in Complex Regional Pain Syndromes in 60 participants. Enrolling by invitation.
1 October 2026
Quick facts
| Lead sponsor | Erasmus Medical Center |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 19 April 2022 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2027 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- S-ketamine infusion inpatient setting — full drug profile →
- S-ketamine infusion outpatient setting — full drug profile →
Conditions studied
- Complex Regional Pain Syndromes — all drugs for Complex Regional Pain Syndromes →
- CRPS (Complex Regional Pain Syndromes) — all drugs for CRPS (Complex Regional Pain Syndromes) →
Sponsor
Erasmus Medical Center
Who can join
18 and older, any sex, with Complex Regional Pain Syndromes or CRPS (Complex Regional Pain Syndromes). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Intravenous administration of esketamine is an effective recognized therapeutic option in refractory pain in CRPS, which sometimes in at least a part of the patients has a prolonged therapeutic effect. Unfortunately, CRPS literature contains a wide range of ketamine dosing regimens with the result that clinical protocols on dosage and administration are very heterogeneous. The current esketamine regimen in Erasmus MC consists of a 6-day hospital admission for continuous administration. In the Netherlands, both inpatient and outpatient esketamine treatments are offered. Inpatient and outpatient ketamine treatments have never been compared in randomized controlled trials and it is therefore unknown whether these two dosing regimens are equally effective. The primary objective is to demonstrate non-inferiority of experimental esketamine administration of 6x 1 day per 2 weeks (in total 3 months) as compared with standard esketamine administration of 1x 6 consecutive days. The end of study is at 6 months after the start of the study/treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Intermittent versus continuous esketamine infusions for long-term pain modulation in complex regional pain syndrome: protocol of a randomized controlled non-inferiority study (KetCRPS-2).
Mangnus TJP, Dirckx M, Bharwani KD, Baart SJ, et al · · 2023 · cited 3× · PMID 36991381 · DOI 10.1186/s12891-023-06258-4
Verify or expand the search:
- PubMed search for NCT05212571
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Complex Regional Pain Syndromes
Currently open trials in the same condition.
- NCT05986461 — Spatially Transcriptomics Reveals Molecular Signatures in CRPS · recruiting
- NCT05814497 — Supraspinal Processing of Sensory Aspects of Pain · NA · recruiting
- NCT05593237 — Transcranial Magnetic Stimulation for Chronic Neuropathic Pain · NA · active not recruiting
- NCT05337501 — Prognostic Factors for Complex Regional Pain Syndrome · NA · active not recruiting
- NCT04144972 — Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain · NA · recruiting
Other Erasmus Medical Center trials
Trials by the same sponsor.
- NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
- NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
- NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
- NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
- NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05212571 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
- Last refreshed: 11 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05212571.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing